COPD

Adamis Pharma Announces Optimistic Results for Beclomethasone Dipropionate HFA Product for Asthma and COPD

COPD, News
Adamis Pharmaceuticals Corporation recently announced promising outcomes from the pharmacokinetic assessment of its beclomethasone dipropionate HFA product APC-1000 for asthma and COPD. This study was a Phase I, randomized, open label, single-dose, four-way crossover pharmacokinetic evaluation comparing the company’s APC-1000 (Beclomethasone Dipropionate HFA, ... Read more